Fuel Your Cell Therapy Research with Large Animal Apheresis Products
In their experience of creating custom programs for hundreds of unique cell, gene and biologic therapies, our team has found that there are times when human source cells are unavailable or not the right product for certain studies. For example, GLP safety evaluation of a personalized gene therapy might be hampered by a lack of human cell test article, or a therapy that doesn’t cross-react with NHP cells may require the creation of an NHP-specific protein. Moreover, our scientists have seen numerous areas of research that really benefit from the application of nonhuman cellular products, though these have not been readily available and difficult to procure.
Large Animal Mobilized Apheresis
Seeking a solution for this critical unmet need, scientists at Charles River have developed a humane method for obtaining cellular products from large animals. Apheresis is a medical technique that harvests cells via extracorporeal circulation so that cellular products may be isolated for research purposes. Commonly used for human donors, the technique has never been available for use in animals, until now.
More Options for Your Cell and Gene Therapy Programs
Our innovative mobilized apheresis capabilities deliver a variety of nonhuman source cell types (e.g., lymphocytes or leukocytes, erythrocytes, and plasma) to create a custom cell therapy product. We can also use our cell mobilization protocols to enhance the isolation of desired cell types and perform same-day analysis of products. Integrating with our in-house flow cytometry and other analytical modalities, we can deliver real-time cell product analysis to investigate biochemical or immunological signaling pathways. Our cryopreservation capabilities provide extended access to cells for later use.
Applications for Nonhuman Cellular Products
In addition to meeting identified needs, this exciting new technology opens a wide range of research applications, from fresh cell gene editing to cell sorting and expansion for allograft and autograft cell therapy research in nonclinical models.
- Proof of concept/discovery work
- Ex vivo gene therapy research with cryopreserved stem cells, B, T and NK cells
- Create NHP-specific protein to evaluate safety of products that do not cross-react with NHP tissues
- Mimic human studies – work with an NHP equivalent product that has better targeting
- Gene editing of selected cell types (e.g. stem cells, lymphocytes, NK cells, etc.)
- Translational research – relevant surrogate to study clinical scenarios for cell therapy applications while using nonclinical research models
Paving the Way for Next Generation Therapies
With gene editing advances, cell therapy research is now ready for applied medical research with the potential to provide next-generation therapies for patients worldwide. Precision medicine is becoming the new medical standard and there lies a critical need to develop cell therapy technologies to enable personalized treatment to patients suffering from a multitude of diseases ranging from autoimmune disorders to different cancer types or orphan indications.
As examples, stem cell and CAR-T therapies have emerged to become leading therapeutic solutions with more and more research providing evidence on the value of using cell therapies in a broad range of therapeutic indications. Although much headway has been made in exploring the possibility of using stem cells or CAR-T as a primary treatment, there remain many unanswered questions yet to be explored, including gene editing technologies for regenerative medicine or cell function and characterization when developing autograft cell therapies. The advent of large animal apheresis and primary cell products will certainly contribute to advancing the pioneering research efforts for upcoming generations of cell therapies.
Still have questions on how we can help you navigate challenges with your cellular therapy programs?